SCHEMBL5885645

SCHEMBL5885645

Cc1cc(C#CCN(Cc2cccnc2)c2cccc(C(=N)N)c2)ccc1C(=O)N1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.39
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
F10 P00742 6/20 0.36
F2 P00734 2/20 0.36
PDK1 Q15118 1/20 0.36
PTGES O14684 3/20 0.36
AKR1C3 P42330 2/20 0.36
CNR2 P34972 1/20 0.35
NAMPT P43490 2/20 0.35
GRM2 Q14416 1/20 0.35
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5885733 0.99 ACACB (0.38) ACACBABL1BCRF10F2
SCHEMBL5885594 0.91 ACACB (0.42) ACACBF10F2PRSS1PRSS2
Hydrochloric Acid SCHEMBL5885611 0.90 ACACB (0.41) ACACBF10F2PRSS1PRSS2
SCHEMBL5885693 0.89 ACACB (0.40) ACACBF10F2PRSS1PRSS2
Hydrochloric Acid SCHEMBL5885675 0.88 ACACB (0.40) ACACBF10F2PRSS1PRSS2
SCHEMBL5885865 0.88 ACACB (0.42) ACACBF10F2PRSS1PRSS2
SCHEMBL5885627 0.87 PDK1 (0.40) ACACBPDK1PTGESAKR1C3CNR2
Hydrochloric Acid SCHEMBL5886162 0.87 ACACB (0.42) ACACBF10F2PRSS1PRSS2
SCHEMBL5885679 0.87 ACACB (0.40) ACACBF10F2PRSS1PRSS2
Hydrochloric Acid SCHEMBL5885550 0.86 ACACB (0.40) ACACBF10F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005437-B2 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-02-28 US claimed
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-06 US claimed
US-7005437-B2 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-02-28 US disclosed
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions F2, F12, F3 ACACB 2639/4885ABL1 402/4885BCR 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.